Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zhejiang HygeianCells BioMedical (also known as Chuyuan Biotechnology) is a clinical-stage Chinese biotechnology company focused on developing regenerative medicine therapies. The company's core technology platform centers on animal early embryo extract, specifically chick early amniotic fluid (ceAF), which is a cell-free preparation containing composite growth-promoting factors and inflammatory inhibitors. Its lead investigational candidate, EE001, is being evaluated in Phase 1 clinical trials for cardiac insufficiency (heart failure) and knee osteoarthritis. Additionally, the company is conducting preclinical research on ceAF for applications in cutaneous wound healing, diabetic foot ulcers, and oncology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zhejiang HygeianCells BioMedical.